| Field |
Value |
| Experiment ID |
DLB-TAU-COPATH-001 |
| Category |
Basic Mechanism / Biomarker |
| Disease |
Dementia with Lewy Bodies |
| Rank |
108 |
| Score |
71 |
How does tau co-pathology (30-50% of DLB cases) influence clinical presentation, disease progression, treatment response, and overall prognosis? Can tau PET imaging distinguish DLB phenotypes and guide therapeutic decisions?
-
DLB patients with significant tau co-pathology present with:
- More rapid cognitive decline
- Earlier and more severe memory impairment
- Reduced response to cholinesterase inhibitors
- Different pattern of neuroanatomical involvement
-
Tau PET can identify DLB subtypes with different:
- Progression trajectories
- Treatment responses
- Expected clinical outcomes
- Type: Cross-sectional with longitudinal follow-up
- Cohort: 200 clinically diagnosed DLB patients
- 70 with high tau burden (PET+)
- 70 with low tau burden (PET-)
- 60 intermediate
- Follow-up: 2 years
Imaging
- Tau PET: ^18F-MK-6240 or ^18F-APN-1607
- Amyloid PET: ^11C-PiB or ^18F-florbetapir
- FDG-PET for hypometabolism patterns
- MRI for structural volumes
- Dopaminergic imaging: DaTscan
Clinical
- Comprehensive cognitive battery (ADAS-Cog13, MMSE, MoCA)
- Motor assessment (UPDRS, HY staging)
- Psychiatric (NPI, BPRS, GDS)
- Autonomic function testing
- Functional capacity (ADL, FAQ)
Biomarkers
- CSF: total tau, p-tau181, p-tau217, alpha-synuclein seeding assay, NfL
- Blood: p-tau181, p-tau217, NfL, GFAP
Primary: Human DLB cohort with multimodal imaging
Secondary:
- Postmortem brain tissue from DLB cases with/without tau (confirmed neuropathology)
- Mouse models with combined tau/alpha-syn expression
- Primary: Define tau burden thresholds that predict distinct clinical phenotypes
- Secondary: Identify biomarker panels that distinguish tau+ from tau- DLB
- Exploratory: Determine if anti-tau therapy should be prioritized for tau+ DLB patients
| Dimension |
Score |
Notes |
| Technical |
9/10 |
Tau PET tracers available, established protocols |
| Recruitment |
8/10 |
DLB clinics can identify patients; need amyloid PET |
| Cost |
6/10 |
Tau PET expensive, ~$5M over 2 years |
| Timeline |
8/10 |
2-year study feasible |
Estimated Cost: $4.5-5.0M over 2 years
Estimated Duration: 18 months enrollment + 12 months follow-up + 6 months analysis
| Finding |
Clinical Application |
| Tau+ DLB responds less to AChEIs |
Consider alternative treatments earlier |
| Tau burden predicts progression rate |
Enrich clinical trials for rapid progressors |
| Distinct imaging patterns |
Use PET for patient stratification |
| Biomarker correlates |
Blood tests to identify tau co-pathology |